Recent IBRX News
- The $13 Million Company Teaching the Immune System to Hunt Cancer • PR Newswire (Canada) • 05/29/2026 01:00:00 PM
- The $13 Million Company Teaching the Immune System to Hunt Cancer • PR Newswire (US) • 05/29/2026 01:00:00 PM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX • PR Newswire (US) • 05/26/2026 01:00:00 PM
- ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS • Business Wire • 05/22/2026 11:30:00 AM
- ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation • Business Wire • 05/22/2026 11:30:00 AM
- ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 • Business Wire • 05/20/2026 12:30:00 AM
- Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 05/19/2026 01:00:00 PM
- Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes • PR Newswire (US) • 05/19/2026 01:00:00 PM
- Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes • PR Newswire (Canada) • 05/19/2026 01:00:00 PM
- ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 • Business Wire • 05/19/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/18/2026 09:20:47 PM
- ImmunityBio Shares Rise After Securing Five New U.S. Patents for Bladder Cancer Therapy (IBRX) • IH Market News • 05/18/2026 02:35:29 PM
- ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035 • Business Wire • 05/18/2026 11:30:00 AM
- ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States • Business Wire • 05/16/2026 05:35:00 PM
- ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX • PR Newswire (US) • 05/14/2026 07:23:00 AM
- Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 05/12/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:32:40 AM
- ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million • Business Wire • 05/07/2026 11:30:00 AM
- ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting • Business Wire • 05/05/2026 11:30:00 AM
- IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt • PR Newswire (US) • 04/30/2026 01:00:00 PM
- IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt • PR Newswire (US) • 04/23/2026 01:00:00 PM
- IBRX Shareholder Alert: May 26, 2026 Lead Plaintiff Deadline in ImmunityBio, Inc. Securities Class Action Lawsuit -- The Gross Law Firm • PR Newswire (US) • 04/21/2026 01:00:00 PM
- ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership • Business Wire • 04/21/2026 11:30:00 AM
- ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX • PR Newswire (US) • 04/20/2026 07:09:00 AM
- IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt • PR Newswire (US) • 04/16/2026 01:00:00 PM
